---
title: "Halozyme director Bernadette Connaughton disposes of 1.626 shares worth $167.152,8"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295584667.md"
description: "Halozyme Therapeutics director Bernadette Connaughton sold 1,626 shares of common stock on August 10, 2026, at a price of $102.8 per share, totaling approximately $167,152.8. Following this transaction, her direct ownership decreased to 40,418 shares. The information was published via EDGAR by Halozyme Therapeutics Inc."
datetime: "2026-08-11T21:44:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295584667.md)
  - [en](https://longbridge.com/en/news/295584667.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295584667.md)
---

# Halozyme director Bernadette Connaughton disposes of 1.626 shares worth $167.152,8

-   Direktur Bernadette Connaughton menjual 1.626 saham common stock Halozyme Therapeutics pada 10 Agustus 2026. \* Transaksi tercatat pada harga USD 102,8 per saham. \* Kepemilikan langsungnya turun menjadi 40.418 saham setelah transaksi. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001662521-26-000002), on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)

## Related News & Research

- [Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock](https://longbridge.com/en/news/295589663.md)
- [Halozyme Q2 revenue jumps 48%, raises 2026 outlook](https://longbridge.com/en/news/295138020.md)
- [Ton Strategy CEO Kevin Mark Wilson reports $19,509 common share purchase](https://longbridge.com/en/news/295975374.md)
- [Vaderis Therapeutics raises $152 million in Series B financing](https://longbridge.com/en/news/295667421.md)
- [TON Strategy (TONX) Stock Chases Staking Windfall While Gram Swings Loom](https://longbridge.com/en/news/295609155.md)